

Karyopharm Therapeutics Inc. (KPTI)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001503802

Karyopharm Therapeutics Inc. KPTI; healthcare	
Grade	E A B C D E weakest fifth of 371 graded peers percentile 83.2; sampling error 2.5 points; lower is stronger
Rank	309 of 371
Profitability	A percentile 4.6
Solvency	E percentile 92.3
Growth and financing	E percentile 85.0
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$108.4M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	dilution, distress; fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 13, 2026 238 days before the rescen; latest periodic filing 10-Q received Aug 13, 2026
Last close	\$0.60 2026-10-08; market equity \$13.7M
Price used in grade	None

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 13, 2026

We are a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer. Our scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 ("XPO1").

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 4.6						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			a prior annual debt, equity, and cash observation is required
Accruals ratio		(88.5%)	(6.6%)	4.6	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 92.3						
Twelve-month failure probability		22.95%	0.07%	99.6	248	2026-06-30
Altman Z double-prime		(58.62)	(0.31)	90.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		1.12x	2.96x	87.2	839	2025-12-31
Growth and financing, sleeve percentile 85.0						
Revenue growth, three-year compound		(2.4%)	10.0%	76.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(32.9%)	2.1%	93.7	704	2025-12-31
Net share issuance, one year		118.0%	2.5%	84.4	634	2026-02-05

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 118.0%
Distress	CHS probability 22.949430%; universe top-decile threshold 1.068854%
Fortress balance sheet	cash minus debt is 21,166,000 USD; Altman Z is not used



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
304	Personalis, Inc. (PSNL)	81.9	D/E	
305	Accuray Inc. (ARRAY)	82.2	D/E	late filer
306	Moderna, Inc. (MRNA)	82.4	D/E	
307	Stereotaxis, Inc. (STXS)	82.7	E	
308	SkinHealth Systems Inc. (SKIN)	83.0	E	
309	Karyopharm Therapeutics Inc. (KPTI) <	83.2	E	dilution, distress, fortress balance sheet
310	Novavax Inc. (NVAX)	83.5	E	
311	Pyxis Oncology, Inc. (PYXS)	83.8	E	short runway, distress
312	Opko Health, Inc. (OPK)	84.1	E	fortress balance sheet
313	Amarin Corp. Plc\Uk (AMRN)	84.3	E	fortress balance sheet
314	Kalaris Therapeutics, Inc. (KLRS)	84.6	E	dilution

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(68.5%)	8.0%	7
Distance from 52-week high	(94.4%)	(31.4%)	3
EBIT to enterprise value	(70.9%)	(1.5%)	10
Free cash flow yield	(553.8%)	(1.0%)	1
Book value to price	(24.26)	0.28	0
Sales to price	10.73	0.31	99
Composite equity issuance, five years	151.7%	20.3%	85
Relative strength against the sector, log excess return	(1.37)	(0.14)	7

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$55.0M
Operating cash flow, four quarters	-\$65.3M
Months of runway	10.1
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$2.3M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	-\$98.3M	2021-12-31	2024-02-29	10-K	0000950170-24-022650
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$113.8M	2021-12-31	2024-02-29	10-K	0000950170-24-022650
3	income tax	us-gaap:IncomeTaxExpenseBenefit	\$268,000	2021-12-31	2024-02-29	10-K	0000950170-24-022650
4	total debt	us-gaap:LongTermDebt	\$169.3M	2021-12-31	2022-03-01	10-K	0000950170-22-002548
5	book equity	us-gaap:StockholdersEquity	-\$79.7M	2021-12-31	2025-02-19	10-K	0000950170-25-022765
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$190.5M	2021-12-31	2024-02-29	10-K	0000950170-24-022650
7	net income	us-gaap:NetIncomeLoss	-\$196.0M	2025-12-31	2026-02-13	10-K	0001193125-26-049397
8	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$75.4M	2025-12-31	2026-02-13	10-K	0001193125-26-049397
9	assets	us-gaap:Assets	\$108.4M	2025-12-31	2026-02-13	10-K	0001193125-26-049397
10	assets	us-gaap:Assets	\$164.4M	2024-12-31	2026-02-13	10-K	0001193125-26-049397
11	current assets	us-gaap:AssetsCurrent	\$103.1M	2025-12-31	2026-02-13	10-K	0001193125-26-049397
12	current liabilities	us-gaap:LiabilitiesCurrent	\$92.1M	2025-12-31	2026-02-13	10-K	0001193125-26-049397
13	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.8B	2025-12-31	2026-02-13	10-K	0001193125-26-049397
14	operating income	us-gaap:OperatingIncomeLoss	-\$90.7M	2025-12-31	2026-02-13	10-K	0001193125-26-049397
15	book equity	us-gaap:StockholdersEquity	-\$292.9M	2025-12-31	2026-02-13	10-K	0001193125-26-049397
16	liabilities	us-gaap:Liabilities	\$401.3M	2025-12-31	2026-02-13	10-K	0001193125-26-049397
17	depreciation amortization	us-gaap:Depreciation	\$789,000	2021-12-31	2024-02-29	10-K	0000950170-24-022650
18	operating income	us-gaap:OperatingIncomeLoss	-\$129.5M	2023-12-31	2026-02-13	10-K	0001193125-26-049397
19	interest expense	us-gaap:InterestExpense	\$23.8M	2023-12-31	2024-02-29	10-K	0000950170-24-022650
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$146.1M	2025-12-31	2026-02-13	10-K	0001193125-26-049397
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$145.2M	2024-12-31	2026-02-13	10-K	0001193125-26-049397
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$146.0M	2023-12-31	2026-02-13	10-K	0001193125-26-049397
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$157.1M	2022-12-31	2025-02-19	10-K	0000950170-25-022765
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2025-12-31	2026-02-13	10-K	0001193125-26-049397
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$127.5M	2024-12-31	2026-02-13	10-K	0001193125-26-049397
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$142,000	2024-12-31	2026-02-13	10-K	0001193125-26-049397
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$92.7M	2023-12-31	2026-02-13	10-K	0001193125-26-049397
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2023-12-31	2026-02-13	10-K	0001193125-26-049397
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$149.6M	2022-12-31	2025-02-19	10-K	0000950170-25-022765
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$118,000	2022-12-31	2025-02-19	10-K	0000950170-25-022765
31	depreciation amortization	us-gaap:Depreciation	\$296,000	2025-12-31	2026-02-13	10-K	0001193125-26-049397
32	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$116.0M	2021-12-31	2026-02-13	10-K	0001193125-26-049397
33	income tax	us-gaap:IncomeTaxExpenseBenefit	\$43,000	2025-12-31	2026-02-13	10-K	0001193125-26-049397
34	current assets	us-gaap:AssetsCurrent	\$156.5M	2024-12-31	2026-02-13	10-K	0001193125-26-049397
35	current liabilities	us-gaap:LiabilitiesCurrent	\$92.3M	2024-12-31	2026-02-13	10-K	0001193125-26-049397
36	assets	us-gaap:Assets	\$240.4M	2023-12-31	2025-02-19	10-K	0000950170-25-022765
37	assets	us-gaap:Assets	\$358.2M	2022-12-31	2024-02-29	10-K	0000950170-24-022650
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	18,343,968	2026-02-05	2026-02-13	10-K	0001193125-26-049397
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	126,240,054	2025-02-14	2025-02-19	10-K	0000950170-25-022765